

(FILE 'HOME' ENTERED AT 14:53:57 ON 31 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, CONFSCI, EMBASE'

ENTERED AT 14:54:53 ON 31 JUL 2002

262821 S CHIMER? OR FUSION (A) PROTEIN

68286 S L1 AND ENZYME?

23802 S L2 AND TARGET?

12964 S L3 AND ADMIN?

1091 S L4 AND PRODRUG

1065 DUP REM L5 (26 DUPLICATES REMOVED)

36 S L6 NOT PY=>1997

=> d 1-36 17

L7 ANSWER 1 OF 36 MEDLINE

AN 1998040658 MEDLINE

DN 98040658 Pubmed ID: 9373327

TI In vitro and in vivo characterisation of a recombinant carboxypeptidase

G2::anti-CEA scFv fusion protein.

AU Michael N P; Chester K A; Melton R G; Robson L; Nicholas W; Boden J A;

Pedley R B; Begent R H; Sherwood R F; Minton N P

Department of Molecular Microbiology, Centre for Applied Microbiology and

Research, Wiltshire, UK.

SO IMMUNOTECHNOLOGY. (1996 Feb) 2 (1) 47-57.

Journal code: 9511979. ISSN: 1380-2933.

CY Netherlands

DT Journal: Article: (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199712

ED Entered STN: 19980109

Last Updated on STN: 20000303

Entered Medline: 19971215

L7 ANSWER 2 OF 36 MEDLINE

AN 97126554 MEDLINE

DN 97126554 Pubmed ID: 8971469

TI Monoclonal antibody-based therapy.

AU Von Mehren M; Weiner L M

Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

SO CURRENT OPINION IN ONCOLOGY. (1996 Nov) 8 (6) 493-8. Ref: 34

Journal code: 9007265. ISSN: 1040-8746.

CY United States

DT Journal: Article: (JOURNAL ARTICLE)

General Review: (REVIEW)

(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199704

ED Entered STN: 19970422

Last Updated on STN: 19970422

Entered Medline: 19970404

L7 ANSWER 3 OF 36 CANCERLIT

AN 90658782 CANCERLIT

DN 90658782

TI FOURTH INTERNATIONAL CONFERENCE ON MONOCLONAL ANTIBODY IMMUNOCONJUGATES

FOR CANCER. MARCH 30-APRIL 1, 1989, SAN DIEGO, CA.

AU Anonymous

CS No affiliation given.

SO Non-serial. (1989) Fourth International Conference on Monoclonal Antibody

Immunocjugates for Cancer. March 30-April 1, 1989, San Diego, CA. UCSF

Cancer Center, 229 P., 1989.

DT Book: (MONOGRAPH)

LA English

FS Institute for Cell and Developmental Biology

EM 199002

ED Entered STN: 19941107

Last Updated on STN: 19941107

L7 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2002 ACS

AN 1995:893179 CAPLUS

DN 123:328961

TI Prodrugs in medicine

Comore, Tom A.; Knox, Richard J.

Centre for Polymer Therapeutics, School of Pharmacy, London, WC1N 1AX, UK

CS Expert Opin. Ther. Pat. (1995). Volume Date 1995, 5(9), 873-85

SO CODEN: EOPRPG; ISSN: 1354-3776

DT Journal: General Review

LA English

L7 ANSWER 5 OF 36 USPATFULL

AN 96:108662 USPATFULL

TI Three-step pretargeting methods using improved biotin-active agent

Theodore, Louis J.; Lynnwood, WA, United States

Reno, John M.; Brier, WA, United States

Gustavson, Linda M.; Seattle, WA, United States (U.S. corporation)

US 5578287

US 1993-156614 19931123 (8)

Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992,

now abandoned which is a continuation-in-part of Ser. No. US

1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

Utility

DT Granted

FS

LN.CNT 2318

INCL

INCLM: 424/001.490

INCLS: 424/009.363; 424/001.530; 548/303.700; 514/387.000; 540/474.000;

530/391.500; 530/391.300; 530/391.100

NCLM: 424/001.490

NCLS: 424/001.530; 424/009.363; 514/387.000; 530/391.100; 530/391.300;

530/391.500; 540/474.000; 548/303.700

IC

[6] ICM: A61K051-10

ICS: A61K031-415; C07D016-30; C07D257-02

424/1.1; 424/85.8; 424/1.49; 424/1.53; 424/9.363; 530/391.1; 530/391.5;

530/391.3; 548/304; 514/387; 540/474

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 36 USPATFULL

AN 96:106192 USPATFULL

TI Heterovesicular liposomes

Kim, Shih, Solana Beach, CA, United States

Depotech Corporation, San Diego, CA, United States (U.S. corporation)

US 5576017 19961119

US 1995-393724 19950223 (8)

Continuation-in-part of Ser. No. US 1993-78701, filed on 16 Jun 1993,

now patented, Pat. No. US 5422120 which is a continuation-in-part of

Ser. No. US 1990-496846, filed on 21 Mar 1990, now abandoned which is a

continuation-in-part of Ser. No. US 1988-196590, filed on 30 May 1988,

now abandoned

Utility

DT Granted

FS

LN.CNT 585

INCL

INCLM: 424/450.000

INCLS: 264/004.100; 264/004.300; 436/829.000

NCLM: 424/450.000

NCLS: 264/004.100; 264/004.300; 436/829.000

IC [6]  
 ICM: A61K009-127  
 EXF 424/450; 436/829; 264/4.1; 264/4.3  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 36 USPATFULL  
 TI 96:101658 USPATFULL  
 TI Recombinant antibodies specific for a growth factor receptor  
 IN Wells, Winfried S., Basel, Switzerland  
 Hyman, Nancy E., Basel, Switzerland  
 Harreth, Ina-Maria, Grenzach-Wyhlen, Germany, Federal Republic of  
 Groner, Bernd, Basel, Switzerland  
 Hardman, Norman, Riehen, Switzerland  
 Zwickli, Markus, Basel, Switzerland  
 Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)  
 PA US 5571884  
 PI US 1994-235838 19940429 (8)  
 RLI Continuation of Ser. No. US 1992-828832, filed on 31 Jan 1992, now  
 abandoned which is a continuation-in-part of Ser. No. US 1991-731190,  
 filed on 15 Jul 1991, now abandoned  
 EP 1991-810079 19910205

PRAI  
 DT Utility  
 FS Granted  
 LN.CNT 3057  
 INCL INCLM: 530/387.300  
 INCLM: 435/064.100; 530/350.000; 536/023.400  
 NCL NCLM: 530/387.300  
 NCLM: 435/069.100; 530/350.000; 536/023.400  
 IC [6]  
 ICM: C07K016-28  
 EXF 435/69.7; 435/252.3; 425/320.1; 530/350; 530/387.3; 536/23.4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 36 USPATFULL  
 AN 96:101609 USPATFULL  
 TI Nitroaniline derivatives and their use as anti-tumour agents  
 IN Denny, William A., Auckland, New Zealand  
 Palmer, Brian D., Auckland, New Zealand  
 Wilson, William R., Auckland, New Zealand  
 Cancer Research Campaign Technology Limited, London, England (non-U.S.  
 corporation)  
 PA US 5571845 19961105  
 PI WO 9311099 19930610 #STR1#  
 AI US 1994-244449 19940526 (8)  
 WO 1992-CB2199 19940526 PCT 371 date  
 19940526 PCT 102(e) date  
 19911128

PRAI NZ 1991-240785 19911128  
 DT Utility  
 FS Granted  
 LN.CNT 1157  
 INCL INCLM: 514/619.000  
 INCLM: 564/166.000; 564/163.000; 564/145.000  
 NCL NCLM: 514/619.000  
 NCLM: 564/145.000; 564/163.000; 564/166.000  
 IC [6]  
 ICM: A01N037-18  
 EXF 564/166; 564/163; 564/145; 514/619  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 36 USPATFULL  
 AN 96:12796 USPATFULL

TI Thermally stable cytosine deaminase from saccharomyces  
 IN Senter, Peter D., Seattle, WA, United States  
 Su, Peter C., Mercer Island, WA, United States  
 Margardt, Hans, Mercer Island, WA, United States  
 Hayden, Martha S., Seattle, WA, United States  
 Linsley, Peter, Seattle, WA, United States  
 Oncogen, Seattle, WA, United States (U.S. corporation)  
 PA US 5545948 19960813  
 PI US 1994-262238 19940620 (8)  
 RLI Division of Ser. No. US 1990-531646, filed on 1 Jun 1990, now patented,  
 Pat. No. US 5338678 which is a continuation-in-part of Ser. No. US  
 1989-365020, filed on 9 Jun 1989, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1271  
 INCL INCLM: 435/227.000  
 NCL NCLM: 435/227.000  
 IC [6]  
 ICM: C12N009-78  
 EXF 435/227  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 36 USPATFULL  
 AN 96:70431 USPATFULL  
 TI Covalent microparticle-drug conjugates for biological targeting  
 IN Yelvin, Milton B., Portland, OR, United States  
 Stowell, Michael H. B., Pasadena, CA, United States  
 Gallicchio, Vincent S., Lexington, KY, United States  
 Meredith, Michael J., Lake Oswego, OR, United States  
 State of Oregon, Acting by and Through the Oregon State Board of Higher  
 Education, Acting for and on behalf of the Oregon Health Sciences  
 University, Portland, OR, United States (U.S. corporation)  
 PA US 5543391 19960806  
 PI US 1995-441770 19950516 (8)  
 RLI Division of Ser. No. US 1994-246941, filed on 19 May 1994 which is a  
 continuation-in-part of Ser. No. US 1993-142771, filed on 26 Oct 1993  
 which is a continuation-in-part of Ser. No. US 1992-911209, filed on 9  
 Jul 1992, now patented, Pat. No. US 5256641, issued on 26 Oct 1993 which  
 is a continuation-in-part of Ser. No. US 1990-607982, filed on 1 Nov  
 1990, now patented, Pat. No. US 5149794, issued on 22 Sep 1992  
 DT Utility  
 FS Granted  
 LN.CNT 1532  
 INCL INCLM: 514/002.000  
 INCLM: 514/078.000; 424/450.000; 536/021.000; 536/051.000; 530/300.000;  
 NCL NCLM: 514/002.000  
 NCLM: 530/331.000; 530/329.000  
 NCLM: 424/450.000; 514/078.000; 530/300.000; 530/329.000; 530/331.000;  
 NCLM: 536/021.000; 536/051.000  
 IC [6]  
 ICM: A01N037-18  
 EXF 514/2; 514/78; 536/21; 536/51; 424/450; 530/300; 530/331; 530/329  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 36 USPATFULL  
 AN 96:70430 USPATFULL  
 TI Covalent microparticle-drug conjugates for biological targeting  
 IN Yelvin, Milton B., Portland, OR, United States  
 Stowell, Michael H. B., Pasadena, CA, United States  
 Gallicchio, Vincent S., Lexington, KY, United States  
 Meredith, Michael J., Lake Oswego, OR, United States  
 State of Oregon, Acting by and Through the Oregon State Board of Higher  
 Education, Acting for and on behalf of the Oregon Health Sciences

University, Portland, OR, United States (U.S. corporation)  
 PI US 5543390 19960806  
 AI US 1994-246941 19940519 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-142771, filed on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1992-911209, filed on 9 Jul 1992, now patented, Pat. No. US 5256641, issued on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1990-607982, filed on 1 Nov 1990, now patented, Pat. No. US 5149794, issued on 22 Sep 1992

DT Utility  
 FS Granted  
 INCL INCLM: 514/002.000  
 INCLS: 424/450.000; 536/051.000; 536/078.000; 536/028.200; 530/300.000; 530/331.000; 530/329.000  
 NCLM: 514/002.000  
 NCLS: 424/450.000; 530/300.000; 530/329.000; 530/331.000; 536/028.200; 536/051.000; 536/078.000

IC [6]  
 ICM: A01N037-18  
 EXF 514/2; 536/29; 536/51; 536/78; 424/450; 530/300; 530/301; 530/329  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 36 USPATFULT.  
 AN 96:68105 USPATFULT.  
 TI Pretargeting methods and compounds  
 IN Yau, Eric K., Kirkland, WA, United States  
 Theodore, Louis J., Lynnwood, WA, United States  
 Gustavson, Linda M., Seattle, WA, United States  
 Neorex Corporation, Seattle, WA, United States (U.S. corporation)  
 PI US 5541287 19960730  
 AI US 1994-345811 19941122 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-156565, filed on 22 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994

DT Utility  
 FS Granted  
 INCL INCLM: 530/317.000  
 INCLS: 530/330.000; 530/331.000; 530/332.000; 530/323.000; 530/345.000  
 NCLM: 530/317.000  
 NCLS: 530/323.000; 530/330.000; 530/331.000; 530/332.000; 530/345.000

IC [6]  
 ICM: A61K038-12  
 EXF 530/317; 530/332; 530/331; 530/323; 530/345  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 36 USPATFULT.  
 AN 96:65461 USPATFULT.  
 TI Prostate-specific membrane antigen  
 IN Israeli, Ron S., Forest Hills, NY, United States  
 Heaton, Warren D. W., New York, NY, United States  
 Fair, William R., New York, NY, United States  
 Sloan-Kettering Institute For Cancer Research, New York, NY, United States (U.S. corporation)  
 PI US 5538866 19960723  
 AI US 1994-325553 19941018 (8)  
 RLI Continuation of Ser. No. US 1992-973337, filed on 5 Nov 1992, now abandoned

DT Utility  
 FS Granted  
 INCL INCLM: 530/317.000  
 INCLS: 530/332; 530/331; 530/323; 530/345  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 435/069.300  
 INCLS: 435/252.300; 435/320.500; 435/240.200; 435/254.200; 935/012.000;  
 NCLM: 435/069.300  
 NCLS: 435/252.300; 435/254.200; 435/320.100; 435/325.000; 435/348.000;  
 IC [6]  
 ICM: C12N015-12  
 EXF 435/69.3; 435/320.1; 435/252.3; 435/254.2; 435/240.2; 935/8; 935/12;  
 935/23; 935/24; 935/27; 935/66; 935/70; 935/72; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 36 USPATFULT.  
 AN 96:58107 USPATFULT.  
 TI Methods and compositions for sequence-specific hybridization of RNA by  
 IN 2'-5' oligonucleotides  
 PA Alul, Rushdi, Columbia, MD, United States  
 Dyad Pharmaceutical Corporation, Columbia, MD, United States (U.S. corporation)  
 PI US 5532130 19960702  
 AI US 1993-93757 19930720 (8)  
 DT Utility  
 FS Granted  
 INCL INCLM: 435/006.000  
 INCLS: 536/023.100; 536/024.300; 536/025.200; 935/078.000  
 NCLM: 435/006.000  
 NCLS: 536/023.100; 536/024.300; 536/025.200

IC [6]  
 ICM: C12Q001-68  
 EXF 514/44; 536/23.1; 536/24.5; 536/25.2; 536/24.3; 935/78; 435/6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 36 USPATFULT.  
 AN 96:43543 USPATFULT.  
 TI ST receptor binding compounds and methods of using the same  
 IN Waldman, Scott A., Ardmore, PA, United States  
 PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)  
 PI US 5518888 19960521  
 AI US 1993-141892 19931026 (8)  
 DT Utility  
 FS Granted  
 INCL INCLM: 435/007.230  
 INCLS: 424/001.690; 424/009.100; 424/009.341  
 NCLM: 435/007.230  
 NCLS: 424/001.690; 424/009.100; 424/009.341

IC [6]  
 ICM: G01N033-574  
 EXF 424/1.49; 424/1.69; 424/9; 424/85.8; 424/9.1; 424/9.341; 435/7.21;  
 435/7.23; 530/388.22; 530/388.26; 530/388.8; 530/389.7; 530/324;  
 530/325; 530/326; 530/327  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 36 USPATFULT.  
 AN 96:27201 USPATFULT.  
 TI Biotin esters of rapamycin  
 IN Molnar-Kimber, Katherine L., Glenside, PA, United States  
 Ocalin, Timothy D., Waltham, MA, United States  
 Vernon, Steven K., Haverlowm, PA, United States  
 Huang, John J., San Carlos, CA, United States

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 5504091 19960402

AI US 1994-224206 19960414 (8)

RLI Continuation-in-part of Ser. No. US 1993-54654, filed on 23 Apr 1993, now abandoned

DT Utility

FS Granted

LN CNT 805

INCL INCLM: 514/291.000

NCL INCLS: 540/456.000; 435/007.100; 435/975.000; 436/547.000; 436/092.000

IC NCLM: 514/291.000

IC NCLS: 435/007.100; 435/975.000; 436/092.000; 436/547.000; 540/456.000

ICM: C07D519-00

ICS: A61K031-395

EXP 540/456; 514/291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 36 USPTAFULL

TI 96:12810 USPTAFULL

IN Monoclonal antibody BR 96 and chimeric monoclonal antibodies having the variable region of MAB BR96, which bind to a variant of ley antigen on human carcinoma cells

HELLSTROM, Karl E., Seattle, WA, United States

BRUCE, Kim F., Seattle, WA, United States

SCHNEIDER, George J., Redmond, WA, United States

PA Oncogen Limited Partnership, United States

PI US 5491088 19960213

AI US 1993-57444 19930505 (8)

RLI Continuation of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned

DT Utility

FS Granted

LN CNT 2238

INCL INCLM: 435/240.240

NCL INCLS: 530/387.300; 530/387.500; 530/388.800; 435/172.200; 435/070.210;

IC NCLM: 435/240.240

IC NCLS: 435/070.210; 530/387.300; 530/387.500; 530/388.800; 530/388.850

ICM: C12N005-20

ICS: C07K016-30

EXP 530/387.3; 530/387.5; 530/388.85; 530/388.8; 435/240.27; 435/70.21;

435/172.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 36 USPTAFULL

TI 96:11071 USPTAFULL

IN Monoclonal antibodies to prostate cells

PASTAN, Ira H., Potomac, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 5489555 19960206

AI US 1992-958140 19921008 (7)

DT Utility

FS Granted

LN CNT 1450

INCL INCLM: 435/007.230

NCL INCLS: 435/007.900; 435/240.270; 436/064.000; 436/813.000; 424/001.490;

530/387.900; 530/388.800; 530/388.850; 530/389.700

IC NCLM: 435/007.230

NCLS: 424/001.490; 435/007.900; 435/344.100; 436/064.000; 436/813.000;

530/387.900; 530/388.800; 530/388.850; 530/389.700

IC ICM: G01N033-53

ICM: G01N033-574

EXP 435/7.23; 435/7.9; 435/240.27; 424/9; 436/64; 436/813; 530/387.7;

530/388.8; 530/388.85; 530/389.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 36 USPTAFULL

TI 95:64726 USPTAFULL

IN Site specific in vivo activation of therapeutic drugs

BREDEHORST, Reinhard, Washington, DC, United States

KIM, Chong-Ho, Rockville, MD, United States

MCCABE, Richard, Rockville, MD, United States

VOGEL, Carl-Wilhelm, Washington, DC, United States

PA Fomato, Nicholas, Frederick, MD, United States

PI Arzo N.V., Arnhem, Netherlands (non-U.S. corporation)

AI US 5433955 19950718

RLI US 1993-134520 19931008 (8)

Continuation of Ser. No. US 1991-720837, filed on 11 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-300999, filed on 23 Jan 1989, now abandoned

DT Utility

FS Granted

LN CNT 960

INCL INCLM: 424/094.300

NCL INCLS: 424/094.610; 530/388.150; 514/034.000; 514/055.000; 536/020.000;

536/006.400; 435/177.000

IC NCLM: 424/094.300

IC NCLS: 424/094.610; 435/177.000; 514/034.000; 514/055.000; 530/388.150;

536/006.400; 536/020.000

ICM: A61K037-58

ICS: A61K031-70; C12N011-06; C07H015-252

EXP 435/7.21; 435/7.23; 435/7.24; 435/206; 435/174; 435/177; 435/178;

424/85.91; 424/94.1; 424/94.3; 424/94.61; 530/388.15; 530/391.1-391.9; 514/34; 514/55; 536/20; 536/6.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 36 USPTAFULL

TI 95:49945 USPTAFULL

IN Heterovesicular liposomes

KIM, Sinil, Solana Beach, CA, United States

PA Depotech Corporation, La Jolla, CA, United States (U.S. corporation)

PI US 5422120 19950606

AI US 1993-76701 19930616 (8)

RLI Continuation-in-part of Ser. No. US 1988-196590, filed on 30 May 1988, now abandoned which is a continuation-in-part of Ser. No. US 1990-496846, filed on 21 Mar 1990, now abandoned

DT Utility

FS Granted

LN CNT 925

INCL INCLM: 424/450.000

NCL INCLS: 264/004.100; 264/004.300; 264/004.600; 436/829.000

IC NCLM: 424/450.000

IC NCLS: 264/004.100; 264/004.300; 264/004.600; 436/829.000

ICM: A61K009-127

ICS: B01J013-02

EXP 424/450; 436/829; 264/4.1; 264/4.3; 264/4.6

424/450; 436/829; 264/4.1; 264/4.3; 264/4.6

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 36 USPTAFULL

AN 95:40852 USPATFUL  
 TI Yeast assay to identify inhibitors of dibasic amino acid processing  
 IN endoproteases  
 IN Franzusoff, Alex, Boulder, CO, United States  
 PA The Regents of the University of Colorado, Boulder, CO, United States  
 PI (U.S. corporation)  
 AI US 5413914  
 AI US 1993-88322  
 DT 19950509  
 DT Utility  
 FS 19930707 (8)  
 INCL  
 IN.CNT 2536  
 ICM: 435/023.000  
 NCL INCLM: 435/007.900; 435/007.910; 435/224.000; 435/810.000; 435/975.000  
 NCLM: 435/023.000  
 NCLS: 435/007.900; 435/007.910; 435/224.000; 435/810.000; 435/975.000  
 IC [6]  
 ICM: C120001-37  
 EXF ICS: C120001-00; C12N009-60  
 435/23; 435/7.9; 435/7.91; 435/183; 435/219; 435/224; 435/810; 435/975  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 36 USPATFUL  
 AN 95:18596 USPATFUL  
 TI Monoclonal antibody L53 which recognizes a human tumor-associated  
 IN antigen  
 IN Hellstrom, Inggerd, Seattle, WA, United States  
 PI Hellstrom, Karl E., Seattle, WA, United States  
 AI Marguardt, Hans, Mercer Island, WA, United States  
 AI Johnston, Janet, Seattle, WA, United States  
 PA Oncogen Limited Partnership, United States (U.S. corporation)  
 PI US 5411884  
 AI US 1993-20256  
 AI US 1993-20256  
 DT 19930218 (8)  
 DT Continuation of Ser. No. US 1990-533371, filed on 5 Jun 1990, now  
 RLI abandoned  
 FS Utility  
 INCL  
 IN.CNT 1146  
 ICM: 435/240.270  
 NCL INCLM: 530/388.150; 530/388.300; 530/387.300; 530/391.300; 530/387.900;  
 435/172.200; 435/070.210  
 NCLM: 435/344.100  
 NCLS: 435/070.210; 530/387.300; 530/387.900; 530/388.150; 530/388.300;  
 530/391.300  
 IC [6]  
 ICM: C12N005-20  
 EXF ICS: C12N015-02; C07K015-28  
 530/388.15; 530/388.3; 530/387.3; 530/391.3; 530/387.9; 124/85.8;  
 435/172.2; 435/70.21; 435/240.27; 424/133.1; 424/138.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 36 USPATFUL  
 AN 94:110800 USPATFUL  
 TI Use of oxidized polyamines, especially NN'-bis-(3-proprionaldehyde)-1-4-  
 IN diaminebutane (spermine dialdehyde) in graft treatment  
 IN Lau, Catherine Y., Unionville, Canada  
 PA Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S.  
 PI corporation)  
 AI US 5374658  
 AI US 1993-55242  
 AI 19930629 (8)  
 DT Abandoned of Ser. No. US 1992-931667, filed on 19 Aug 1992, now  
 DT abandoned which is a continuation of Ser. No. US 1991-769129, filed on  
 30 Sep 1991, now abandoned which is a continuation-in-part of Ser. No.  
 US 1990-586326, filed on 18 Sep 1990, now patented, Pat. No. US 5171754  
 which is a continuation of Ser. No. US 1988-262760, filed on 26 Oct

DT 1988, now abandoned  
 FS Utility  
 INCL  
 IN.CNT 2690  
 ICM: 514/557.000  
 NCL INCLM: 514/558.000; 514/666.000  
 NCLM: 514/557.000  
 NCLS: 514/558.000; 514/666.000  
 IC [5]  
 ICM: A01N033-08  
 EXF ICS: A61K031-13; A61K031-19; A61K031-20  
 514/557; 514/558; 514/666  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 36 USPATFUL  
 AN 94:70962 USPATFUL  
 TI Expression of DNA sequences encoding a thermally stable cytosine  
 IN deaminase from saccharomyces  
 IN Senter, Peter D., Seattle, WA, United States  
 AI Su, Peter C. D., Mercer Island, WA, United States  
 AI Marguardt, Hans, Mercer Island, WA, United States  
 AI Hayden, Martha S., Seattle, WA, United States  
 PA Insey, Peter, Seattle, WA, United States  
 PA Oncogen, a limited Partnership, Seattle, WA, United States (U.S.  
 PI corporation)  
 AI US 5338678  
 AI US 1990-531646  
 AI 19900601 (7)  
 DT Continuation-in-part of Ser. No. US 1989-365020, filed on 9 Jun 1989,  
 DT now abandoned  
 DT Utility  
 FS 1224  
 INCL  
 IN.CNT 1224  
 ICM: 435/227.000  
 NCL INCLM: 435/240.200; 435/252.300; 435/320.100; 536/023.200; 536/023.740  
 NCLM: 435/227.000  
 NCLS: 435/252.300; 435/320.100; 435/365.000; 536/023.200; 536/023.740  
 IC [5]  
 ICM: C12N005-00  
 EXF ICS: C12N001-20; C12N015-00; C07H015-12  
 536/27; 435/69.1; 435/70.1; 435/70.3; 435/71.1; 435/71.2; 435/183;  
 435/195; 435/227; 435/252.1; 435/256  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 36 USPATFUL  
 AN 94:44736 USPATFUL  
 TI Therapeutic interleukin-2-antibody based fusion  
 IN proteins  
 IN Fell, Jr., Henry P., Redmond, WA, United States  
 PA Gayle, Margit A., Woodinville, WA, United States  
 AI Oncogen, Seattle, WA, United States (U.S. corporation)  
 AI US 5314995  
 AI US 1990-468390  
 AI 19900122 (7)  
 DT Utility  
 FS 661  
 INCL  
 IN.CNT 661  
 ICM: 530/351.000  
 NCL INCLM: 530/387.100; 530/387.300; 530/387.700; 530/388.300; 530/388.400;  
 530/388.500; 530/388.600; 530/388.800; 530/388.850; 530/391.700;  
 530/391.900; 435/069.500; 435/069.520; 435/069.700; 435/070.200;  
 435/069.210; 424/085.800; 424/085.100; 424/085.200; 424/085.910;  
 935/047.000  
 NCLM: 530/351.000  
 NCLS: 424/085.100; 424/085.200; 424/134.100; 424/800.000; 435/069.500;  
 435/069.520; 435/069.700; 435/070.200; 435/070.210; 530/387.100;

530/387.300; 530/387.700; 530/388.300; 530/388.400; 530/388.500;  
530/388.600; 530/388.800; 530/388.850; 530/391.700; 530/391.900

IC [5]  
ICM: C07K013-00

EXF 530/387; 530/389-391; 530/808; 530/810; 530/351; 530/387.1; 530/387.3;  
530/387.7; 530/388.3-388.6; 530/388.8; 530/388.85; 530/391.7; 530/391.9;  
530/866; 530/867; 435/69.5; 435/69.52; 435/69.7; 435/70.2; 435/70.21;  
535/47; 424/85.8; 424/85.1; 424/85.2; 424/85.91

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 26 OF 36 USPATFULT.  
94:31159 USPATFULT.  
5-fluorouridine nucleoside phosphate compounds  
Campbell, David A., East Palo Alto, CA, United States  
Gallo, Mark A., East Palo Alto, CA, United States  
Affymax Technologies N.V., Palo Alto, CA, United States (U.S. corporation)

PI US 5302707 19940412  
AI US 1992-858298 19920326 (7)  
DT Utility  
FS Granted  
LN CNT 1284

INCL INCLM: 536/025.330  
INCLS: 536/025.340; 536/026.800; 536/028.530; 536/028.550; 435/006.000;  
435/069.100; 435/069.300; 435/070.200; 435/089.000; 435/188.500;  
435/240.270; 530/388.900

NCL NCLM: 536/025.330  
NCLS: 435/006.000; 435/069.100; 435/069.300; 435/070.200; 435/089.000;  
435/188.500; 530/388.900; 536/025.340; 536/026.800; 536/028.530;  
536/028.550

IC [5]  
ICM: C07H019-06  
536/26.7; 536/26.8; 536/25.3; 536/25.34; 536/25.33; 536/28.53;  
536/28.55; 514/50; 514/51; 514/85; 435/6; 435/69.3; 435/70.2;  
435/70.21; 435/89; 435/188.5; 435/240.27; 530/388.530/337

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 27 OF 36 USPATFULT.  
93:74206 USPATFULT.  
Monoclonal antibody to human carcinomas  
Hellstrom, Ingegerd, Seattle, WA, United States  
Hellstrom, Karl E., Seattle, WA, United States  
Oncogen, Seattle, WA, United States (U.S. corporation)

PI US 5242824 19930907  
AI US 1989-443696 19891129 (7)  
RLI Continuation-in-part of Ser. No. US 1988-289635, filed on 22 Dec 1988,  
now abandoned  
DT Utility  
FS Granted  
LN CNT 1390

INCL INCLM: 435/240.270  
INCLS: 530/388.800; 530/391.300; 530/387.100  
NCLM: 435/244.000  
NCLS: 530/387.100; 530/388.800; 530/391.300

IC [5]  
ICM: C12N005-12  
ICS: C07K015-28  
424/85.8; 424/85.91; 424/88; 530/387; 530/388; 530/388.8; 530/391.3;  
530/387.1; 435/77; 435/172.2; 435/240.27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 28 OF 36 USPATFULT.  
93:59044 USPATFULT.  
Catalytic antibody components

IN Paul, Sudhir, Omaha, NE, United States  
Powell, Michael J., Gaithersburg, MD, United States  
Massey, Richard J., Rockville, MD, United States  
Kenten, John H., Gaithersburg, MD, United States  
Igen, Inc., Rockville, MD, United States (U.S. corporation)

PI US 5229272 19930720  
AI US 1990-498225 19900323 (7)  
RLI Continuation-in-part of Ser. No. US 1989-343081, filed on 25 Apr 1989  
DT Utility  
FS Granted  
LN CNT 2439

INCL INCLM: 435/068.100  
INCLS: 435/188.500; 435/219.000; 435/226.000; 530/389.200; 530/387.100;  
530/388.240  
NCLM: 435/068.100  
NCLS: 435/188.500; 435/219.000; 435/226.000; 530/387.100; 530/388.240;

IC [5]  
ICM: C12N009-00  
ICS: C12N009-64; C12P021-06  
435/183; 435/188.5; 435/219; 435/226; 435/68.1; 530/387; 530/388;  
530/389.2; 530/388.24

EXF 530/387; 530/387.7; 530/388.8; 530/388.85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 29 OF 36 USPATFULT.  
92:102981 USPATFULT.  
Monoclonal antibody to novel antigen associated with human tumors  
Hellstrom, Ingegerd, Seattle, WA, United States  
Hellstrom, Karl E., Seattle, WA, United States  
Marguardt, Hans, Mercer Island, WA, United States  
Oncogen, Seattle, WA, United States (U.S. corporation)

PI US 5171665 19921215  
AI US 1989-339142 19890417 (7)  
DT Utility  
FS Granted  
LN CNT 1173

INCL INCLM: 435/007.230  
INCLS: 435/007.900; 435/172.200; 435/240.270; 436/548.000; 436/813.000;  
436/064.000; 530/387.700; 530/388.800; 530/388.850  
NCLM: 435/007.230  
NCLS: 435/007.900; 435/329.000; 435/344.100; 436/064.000; 436/548.000;  
436/813.000; 530/387.700; 530/388.800; 530/388.850

IC [5]  
ICM: G01N033-574  
ICS: C12P021-08; C07K015-28  
435/7.23; 435/172.2; 435/240.27; 435/7.9; 436/548; 436/813; 436/64;  
530/387; 530/387.7; 530/388.8; 530/388.85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 30 OF 36 USPATFULT.  
92:61852 USPATFULT.  
Monoclonal antibody to novel antigen associated with human tumors  
Hellstrom, Karl E., Seattle, WA, United States  
Hellstrom, Ingegerd, Seattle, WA, United States  
Marguardt, Hans, Mercer Island, WA, United States  
Yoneyama, Yoshitaka, Bellevue, WA, United States  
Oncogen Limited Partnership, Seattle, WA, United States (U.S. corporation)

PI US 5134075 19920728  
AI US 1989-312640 19890217 (7)  
DT Utility  
FS Granted  
LN CNT 1097

INCL INCLM: 530/387.300

INCL: 435/070.210; 435/172.200; 530/387.900; 530/828.000; 530/388.850;  
 530/388.150; 530/391.300  
 NCL: 530/387.300  
 NCLM: 435/070.210; 435/329.000; 435/344.100; 530/387.900; 530/388.150;  
 530/388.850; 530/391.300; 530/828.000  
 IC [5]  
 ICM: C12N005-00  
 ICS: C07K015-28  
 EXF 530/387; 530/828; 435/172.2; 435/240.26; 435/240.27; 435/972; 435/70.21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L7 ANSWER 31 OF 36 USPTAFULL  
 AN 90.93006 USPTAFULL  
 TI Antibody-enzyme conjugates in combination with  
 IN Sender, Peter D., Seattle, WA, United States  
 Saulnier, Mark G., Middletown, CT, United States  
 Brown, Joseph P., Seattle, WA, United States  
 Kerr, David E., Seattle, WA, United States  
 Bristol-Myers Company, New York, NY, United States (U.S. corporation)  
 PA US 4975278 19901204  
 PI US 1988-211301 19880629 (7)  
 RLI Continuation-in-part of Ser. No. US 1988-161068, filed on 26 Feb 1988,  
 now abandoned which is a continuation-in-part of Ser. No. US 1987-81382,  
 filed on 4 Aug 1987, now abandoned  
 DT Utility  
 FS Granted  
 IN.CNT 2319  
 INCL: 424/094.300  
 INCLM: 424/085.910; 424/094.100; 424/094.600; 514/027.000; 514/033.000;  
 514/034.000; 514/080.000; 530/387.000; 530/389.000; 530/391.000;  
 435/188.000; 435/196.000; 435/200.000; 435/212.000; 435/219.000;  
 536/064.000; 536/018.100  
 NCL: 424/178.100  
 NCLM: 424/094.100; 424/094.300; 424/094.600; 424/133.100; 424/155.100;  
 424/156.100; 435/188.000; 435/196.000; 435/200.000; 435/212.000;  
 435/219.000; 514/027.000; 514/033.000; 514/034.000; 514/080.000;  
 530/387.000; 530/388.800; 530/388.850; 536/006.400; 536/018.100  
 IC [5]  
 ICM: A61K037-48  
 ICS: A61K039-395; C12N011-16; C12N009-96  
 EXF 536/6.4; 536/18.1; 514/34; 514/80; 514/27; 514/33; 424/85.91; 424/94.1;  
 424/94.3; 424/94.6; 530/387; 530/389; 530/391; 435/68; 435/188; 435/196;  
 435/212; 435/219; 435/200  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L7 ANSWER 32 OF 36 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 96110272 EMBASE  
 DN 1996110272  
 TI Antibody-directed enzyme prodrug therapy (ADEPT).  
 AU Melton R.G.; Knox R.J.; Connors T.A.  
 CS Centre Applied Microbiol./Research, Salisbury, Wilts SP4 0JG, United  
 Kingdom  
 SO Drugs of the Future, (1996) 21/2 (167-181).  
 ISSN: 0377-8282 CODEN: DRFUD4  
 CY Spain  
 DT Journal, General Review  
 FS 016 Cancer  
 026 Immunology, Serology and Transplantation  
 030 Pharmacology  
 037 Drug literature Index  
 LA English  
 SL English

L7 ANSWER 33 OF 36 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 95061774 EMBASE  
 DN 1995061774  
 TI Development of a humanized disulfide-stabilized anti-p185(HER2) Fv-beta-  
 lactamase fusion protein for activation of a  
 cephalosporin doxorubicin prodrug.  
 AU Rodrigues M.L.; Presta L.G.; Kottis C.E.; Mordenti J.; Osaka G.;  
 Wong W.L.T.; Nuijens A.; Blackburn B.; Carter P.  
 CS Department of Cell Genetics, Genentech Inc, 460 Point San Bruno  
 Boulevard, South San Francisco, CA 94080-4990, United States  
 SO Cancer Research, (1995) 55/1 (63-70).  
 ISSN: 0008-5472 CODEN: CNREA8  
 CY United States  
 DT Journal, Article  
 FS 016 Cancer  
 037 Pharmacology  
 037 Drug literature Index  
 LA English  
 SL English  
 L7 ANSWER 34 OF 36 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 94348252 EMBASE  
 DN 1994348252  
 TI Antibody-directed enzyme prodrug therapy.  
 AU Bagshawe K.D.  
 CS Medical Oncology, Charing Cross Westminster Med School, London W6 8RP,  
 United Kingdom  
 SO Clinical Pharmacokinetics, (1994) 27/5 (368-376).  
 ISSN: 0312-5963 CODEN: CPKNDH  
 CY New Zealand  
 DT Journal, General Review  
 FS 016 Cancer  
 026 Immunology, Serology and Transplantation  
 030 Pharmacology  
 037 Drug literature Index  
 038 Adverse Reactions titles  
 LA English  
 SL English  
 L7 ANSWER 35 OF 36 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 94141396 EMBASE  
 DN 1994141396  
 TI Tumor-selective prodrug activation by fusion  
 protein-mediated catalysis.  
 AU Boslet K.; Czech U.; Hoffmann D.  
 CS Res. Laboratories of Behringwerke AG, P. O. Box 11 40, D-35001 Marburg,  
 Germany  
 SO Cancer Research, (1994) 54/8 (2151-2159).  
 ISSN: 0008-5472 CODEN: CNREA8  
 CY United States  
 DT Journal, Article  
 FS 016 Cancer  
 030 Pharmacology  
 037 Drug literature Index  
 LA English  
 SL English  
 L7 ANSWER 36 OF 36 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 89237505 EMBASE  
 DN 1989237505  
 TI Antitumor antibodies for therapy.  
 AU Hellstrom I.; Hellstrom K.-E.  
 CS ONCOGEN, Seattle, WA 98121, United States  
 SO Nuclear Medicine and Biology, (1989) 16/6 (613-616).

ISSN: 0883-2897 CODEN: NMBIEO  
CY United Kingdom  
DT Journal  
FS 016 Cancer  
023 Nuclear Medicine  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
LA English  
SL English

=>